BrIDGs is not a grant program. BrIDGs provides expertise and resources to facilitate preclinical drug development.
Instead of receiving grant funds, selected researchers collaborate with NCATS intramural drug development experts. Collaborators leverage the federal government’s contract resources and assistance with establishing and implementing product development plans to generate sufficient data for an Investigational New Drug application to a regulatory agency such as the Food and Drug Administration.
Learn more about the BrIDGs program’s available resources and expertise.